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  Chronic osteomyelitis represents a progressive inflam-
matory process caused by pathogens, resulting in bone 
destruction and sequestrum formation. 
  It may present with periods of quiescence of variable dura-
tion, whereas its occurrence, type, severity and prognosis 
is multifactorial. 
  The ‘gold standard’ for the diagnosis of chronic osteomy-
elitis is the presence of positive bone cultures and histo-
pathologic examination of the bone. 
  Its management remains challenging to the treating physi-
cian, with a multidisciplinary approach involving radiolo-
gists, microbiologists with expertise in infectious diseases, 
orthopaedic surgeons and plastic surgeons. 
  Treatment should be tailored to each patient according 
the severity and duration of symptoms, as well as to the 
clinical and radiological response to treatment. 
  A combined antimicrobial and surgical treatment should 
be considered in all cases, including appropriate dead 
space management and subsequent reconstruction. 
Relapse can occur, even following an apparently success-
ful treatment, which has a major impact on the quality of 
life of patients and is a substantial financial burden to any 
healthcare system.
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Introduction
Osteomyelitis is an ancient disease, which has been present for 
the last 250 million years and was first described in humans by 
Hippocrates.1 It is a progressive inflammatory process caused 
by pathogens, resulting in bone destruction and sequestrum 
formation.2,3 The infection can be limited to the bone, or it can 
propagate to the bone marrow, the periosteum and the 
surrounding soft  tissues.2,4 It represents a major financial bur-
den for every health system and substantially affects the qual-
ity of life of the affected patients and their families.
Chronic osteomyelitis may present as a recurrent or 
intermittent disease. The symptoms and their duration 
may vary considerably, whereas periods of quiescence can 
also be of variable duration. The incidence of relapse fol-
lowing an apparently ‘successful’ treatment remains high, 
making its management challenging for the treating phy-
sician.5 Assumed ‘remission’ should only be claimed after 
at least 12 months of follow-up, while ‘cure’ of the disease 
cannot be safely declared.
Prompt diagnosis and aggressive management of 
chronic osteomyelitis are critical to the prognosis and final 
outcome. Treatment aims to achieve the resolution of the 
infection and restoration of function.6 Historically, lengthy 
antibiotic regimes in combination with extensive surgical 
debridement have been used for its management.6 Even 
though the antibiotic choice, delivery type and duration 
remains controversial,7 it is generally accepted that ade-
quacy of debridement with wide excision remains the most 
important clinical predictor of a successful outcome.8
A good understanding of the aetiopathogenesis and 
pathophysiological features of chronic osteomyelitis, 
along with the understanding of the treatment principles 
and options, is necessary to guide the treating physician 
to a successful outcome.
Classification
Even though several classification systems have been sug-
gested, there is no consensus on which one is the most 
appropriate to use. In general terms, osteomyelitis is char-
acterised as acute or chronic, based on its histopathologi-
cal findings, rather than the duration of the infection.9 
Acute osteomyelitis typically presents two weeks after 
bone infection, characterised by inflammatory bone 
changes.9 By contrast, chronic osteomyelitis typically pre-
sents six or more weeks after bone infection and is charac-
terised by the presence of bone destruction and formation 
of sequestra.9,10
The most widely-used classification system of chronic 
osteomyelitis in adults is the Cierny–Mader classification 
(Table 1).6 It incorporates prognostic factors and deline-
ates treatment for each clinical stage according to the ana-
tomical type and physiological class of the host.11
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Osteomyelitis can also be classified according to the 
mechanism of infection (pathogenesis), as exogenous or 
haematogenous.3 Most commonly, chronic osteomyelitis is 
secondary to direct inoculation of pathogens into the bone 
at the time of trauma, as a result of surgical trauma (i.e. fol-
lowing open reduction and internal fixation of fractures), 
from chronic overlying open wounds or contiguous soft tis-
sue infections.3,9 In haematogenous osteomyelitis, the path-
ogens seed into the bone through the systemic circulation, 
even though this type is predominately encountered in pae-
diatric populations.3,9 In adults, it typically occurs secondar-
ily from a distal site of infection, often involving the vertebral 
bodies of the lower spine and can also be associated with 
inflammation of the adjacent intervertebral discs.2,12
Some authors have suggested the distinction of another 
mechanism of osteomyelitis which is secondary to vascu-
lar insufficiency, as this presents with several distinct clini-
cal and pathophysiological features.2 It predominantly 
occurs in patients suffering from diabetes mellitus and it is 
usually the result of a soft tissue infection of the foot that 
spreads to the bone.2
Epidemiology
The incidence of haematogenous osteomyelitis and the mor-
tality associated with it has dramatically reduced following 
the introduction of antibiotics in the 1940s.1 Nevertheless, 
the incidence of chronic osteomyelitis following contiguous 
focus of infection has apparently increased, especially in 
developed countries.3,13 Possible aetiological factors include 
the ageing of the population, the increased prevalence of 
trauma, the rising prevalence of diabetic foot infections and 
improvements in the diagnosis of the disease.3,14 Trauma-
induced osteomyelitis remains the most common cause,15,16 
with infection rates in open long bone fractures ranging 
between 4% and 64%, whereas recurrence rates following 
bony infection have been reported to be as high as 20% to 
30%.16,17 On the other hand, prosthetic joint infections rep-
resent a relatively new entity of chronic osteomyelitis. Their 
incidence is reported to be as high as 1.5% to 2.5%, even 
though rates of up to 20% have been reported following 
revision surgery.4
Aetiopathogenesis
Compared with other types of tissue, bone is relatively 
resistant to the development of infection.4,12 Nonetheless, 
following a large inoculation of pathogens, or even a 
smaller number of particularly virulent bacteria, infection 
may occur.4,12 The type of pathogen isolated is highly 
dependent on patient-related factors such as age, immune 
status, history of trauma and geographical location.18 
Generally, haematogenous osteomyelitis is monomicro-
bic in nature,12 in contrast to contiguous-focus osteomy-
elitis that is polymicrobic.3,10,12
In adult chronic osteomyelitis, the most commonly 
involved pathogen is by far Staphylococcus aureus 
(S. aureus).3,9 Methicillin-resistant S. aureus (MRSA) has also 
been increasingly isolated from chronic osteomyelitis 
lesions.9 Other causative pathogens include Staphylococcus 
epidermidis, Pseudomonas aeruginosa, Serratia marcescens 
and Escherichia coli.3,9 Mycobacterial and fungal infections 
are generally uncommon and are often associated with 
immunodeficiency.3,9
Following the introduction of pathogens such as S. aureus 
into the bone marrow cavity, regardless of the route of 
access, they adhere to membrane proteins such as fibronec-
tin or collagen receptors, establishing an infection.3 Other 
microbial factors prevent access by host defences or penetra-
tion of the surrounding tissues.2 This is achieved by attacking 
several types of host cells and degrading the  extracellular 
matrix.2 S. aureus has also been reported to survive within 
host cells, a mechanism also used by other pathogens.2
Consequently various pathogens produce a relatively 
impermeable polysaccharide/protein matrix (biofilm)8 
that can be multi-layered and embedded within a glyco-
calyx or within a slime layer.12 Surrounded by the bio-
film, these pathogens present with an altered phenotype 
with regards to growth, gene expression and protein 
production2 that protects them from the host’s defence 
mechanisms and the systemic effect of antibiotics.3,19 
This is in contrast to the initial infectious phase where 
Table 1. Cierny–Mader classification system6
Anatomical type
Type Characteristics
I Medullary osteomyelitis
II Superficial osteomyelitis
III Localised osteomyelitis
IV Diffuse osteomyelitis
Physiological class
Type Characteristics
A Good immune system and delivery
B Compromised locally (BL) or systemically (BS)
C Requires suppressive or no treatment;
Minimal disability;
Treatment worse than disease;
Not a surgical candidate
Factors affecting physiological class
Systemic factors (S) Local factors (L)
Malnutrition
Renal or hepatic failure
Diabetes mellitus
Chronic hypoxia
Immune disease
Extremes of age
Immunosuppression
Immune deficiency
Tobacco abuse
Alcohol abuse
Malignancy
Chronic lymphedema
Venous stasis
Major vessel compromise
Arteritis
Extensive scarring
Radiation fibrosis
Small-vessel disease
Neuropathy
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the bacteria are still in a planktonic phase, having a high 
metabolic and generational rate, a factor that increases 
their sensitivity to common antibiotics.19 The pathogens 
can remain in this state for long periods of time and can 
cause flare-ups many years after the initial inoculation.
The inflammatory factors produced by the pathogens, 
as well as by the host’s leucocytes, along with the com-
pression and obliteration of the vascular network around 
the involved area, represent the main mechanisms of tis-
sue necrosis and bone destruction.2 The resulting avascu-
lar area becomes an ideal harbour for bacteria, as neither 
inflammatory cells nor antibiotic agents can reach it. 
Around this avascular area, there is reactive hyperaemia 
and increased osteoclastic activity, which in turn results in 
localised bone loss and osteoporosis.2 At the same time, 
the osteoblasts deposit periosteal new bone.2
Predisposing factors
Several predisposing factors for development of chronic 
osteomyelitis have been reported. A history of trauma, 
open fractures and surgery are the most commonly 
encountered factors.20 Other factors include diabetes, 
peripheral vascular disease, malnutrition, hypotension, 
chronic steroid use, malignancy, alcoholism, smoking, 
systemic or local immunocompromise, intravenous drug 
use and development of decubitus ulcers.6,9,12,20
Nowadays, the presence of implants is one of the most 
important predisposing factors. Soon after implantation 
they become coated with the host’s proteins, an excellent 
source for attachment of pathogens.12 The biofilm they 
produce protects them from the host’s defence mecha-
nisms so that they can re-activate months or years later.12
Clinical features
The clinical features of chronic osteomyelitis are usually not 
specific and therefore difficult to recognise. It can also be 
difficult to differentiate signs of osteomyelitis from soft tissue 
infection, especially in diabetic patients. A variety of symp-
toms have been reported, ranging from no skin lesions to 
open wounds over fractured bones. Chronic pain, an area 
of erythema around the affected bone, swelling and bone 
tenderness, impaired wound healing often associated with 
tissue necrosis, increased drainage or persistent sinus tracts, 
chills, low grade fever and general malaise are some of the 
most commonly reported clinical symptoms (Fig. 1).2,3,9,10,20 
In neglected cases, patients typically report a cyclical pain 
that increases in severity, is associated with fever and sub-
sides when pus breaks out through the fistula.18
Imaging features
Imaging can help both in the characterisation and differen-
tial diagnosis of osteomyelitis. Plain radiography, a first line 
imaging modality, is of very low sensitivity and specificity. It 
is useful, however, to differentiate osteomyelitis from other 
pathologies such as fractures and malignancies (primary or 
metastatic).9 It can reveal soft tissue swelling, periosteal 
reaction, loss of definition, loss of bone density and osteoly-
sis, as early as 10 to 21 days after the bone infection, but 
may not be detectable until there is a loss of 30% to 50% of 
the bone mineral content.2,9,12,20 Late signs include 
increased bone resorption, formation of sequestra and new 
bone formation in the periosteum or endosteum.20
CT provides the most detailed imaging of the cortical 
bone, being especially useful in the identification of 
sequestra and intra-osseous fistulae.2 It also demonstrates 
both the periosteal reaction and the bone marrow involve-
ment, as well as demonstrating the soft tissue condition at 
an early stage.10,20 Even though in the presence of implants 
its quality degrades, it is routinely used for pre-operative 
planning and to guide biopsies.6,20
MRI has an advantage in assessing the bone marrow and 
the surrounding soft tissues, defining the associated oedema 
and hyperaemia that is present in the very early stages of the 
disease.2,21 It can differentiate bone from soft tissue infections 
and it can also be used as an adjunct in estimating the mar-
gins required for the debridement, or to assess the response 
to therapy.2,20 Nevertheless, it is of limited value in the pres-
ence of implants, scar tissue and recent operations.21
Routine bone scintigraphy has also been used in the 
diagnosis of chronic osteomyelitis. Nonetheless, it is asso-
ciated with a limited specificity and false-positive results, 
especially in patients who have had diabetic arthropathy, 
gout, trauma and recent surgery. Therefore, its use is not 
recommended as a single imaging modality.2,21 Leucocyte 
scintigraphy, on the other hand is reported to be an accu-
rate technique for diagnosing chronic osteomyelitis in the 
peripheral skeleton, but its diagnostic accuracy in the axial 
skeleton is significantly reduced.21 False-positive results 
Fig. 1 Patient presented with a discharging sinus and 
surrounding cellulitis over the distal tibia, 13 months following 
a closed distal tibia fracture that was surgically managed.
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are also reported in the presence of mechanically unstable 
nonunions, or peri-articular nonunions with associated 
post-traumatic arthropathy.20
Positron emission tomography (PET) has the highest sen-
sitivity and specificity, delineating lesions with their con-
comitant inflammatory activity at very early stages.2,18 Its 
availability and associated costs, however, limit its routine 
use.6 However, a meta-analysis investigating the accuracy of 
diagnostic imaging for chronic osteomyelitis, showed that 
fluorodeoxyglucose PET has the highest diagnostic accu-
racy, both for confirming and excluding the diagnosis of 
chronic osteomyelitis, especially in the axial skeleton.21,22
Ultrasonography (US) is mainly used at the early stages 
for detecting purulent collections within the soft tissues.2 
Some authors suggest that in some cases it can be diag-
nostic, but reliable estimates of its specificity and sensitiv-
ity are not available.18
Laboratory evaluation
A number of laboratory investigations can help with the 
diagnosis, even though they generally lack specificity for 
chronic osteomyelitis. The presence of inflammatory mark-
ers such as an increased C-reactive protein (CRP) level and 
increased erythrocyte sedimentation rate (ESR) may be 
used as an adjunct to the diagnosis and for monitoring 
clinical response to treatment.2,3,9,20 By contrast, in most 
cases, the presence of persistently normal CRP and ESR lev-
els usually rules out osteomyelitis, even though in the 
presence of a discharging sinus or a background of diabe-
tes, this may not be the case.9 Leukocytosis and elevated 
alpha-1 acid glycoprotein levels may also be present, but 
these are not reliable indicators.3,9 On the contrary, white 
cell count (WCC) can be within normal limits.10,20
Most importantly, for obtaining a definitive diagnosis in 
chronic osteomyelitis, the presence of positive microbial cul-
tures from bone biopsies around areas of bone necrosis is 
considered essential.9 These should not be obtained from 
superficial wounds or fistulae, as these have been associated 
with low accuracy because of inclusion of non-pathogenic 
micro-organisms that colonise the wound.2,3 False-negative 
results are also reported, mainly because of the patchy dis-
tribution of the osteomyelitis lesions in the bone.2 Often, 
more than one organism is involved and these may include 
anaerobic, mycobacterial and fungal organisms so that spe-
cific cultures and microbiological testing may be necessary.9 
Especially in cases of implant-related osteomyelitis, samples 
from up to five sites around the implant should be obtained 
to increase the diagnostic yield, and prolonged enrichment 
broth cultures are often necessary.2,20 It is very important 
that the cultures are obtained before commencing any anti-
microbial treatment, to avoid false-negative results. Con-
ventional blood cultures are generally useful only in cases of 
haematogenous osteomyelitis.
Histopathology of tissue specimens obtained during 
biopsy or debridement can also provide additional impor-
tant information. Significant presence of neutrophils is 
indicative of infection, whereas positive special staining 
suggests the presence of pathogens earlier than the cul-
ture results.2
Diagnostic approach
The diagnosis of chronic osteomyelitis can often be challeng-
ing, but it is important to realise that an early diagnosis will 
lead to a more favourable outcome. A combination of high 
index of clinical suspicion and recognition of the clinical 
symptoms, along with imaging and laboratory investiga-
tions, can aid the diagnosis. Especially in patients with com-
promised peripheral vasculature, diagnosis of chronic 
osteomyelitis can be even more difficult, as the symptoms 
are usually subtle and systemic features are absent.12 The 
clinical examination should be focussed on identifying a pos-
sible nidus of infection.9 As mentioned, the most sensitive 
criterion is the presence of positive bacterial cultures from 
bone biopsies obtained from areas with bone necrosis.9
Management
The management of chronic osteomyelitis depends on the 
duration and severity of symptoms, as well as the presence 
of medical comorbidities. In most cases, the surrounding 
soft tissue envelope is compromised and the vascularisa-
tion of the area is poor, a factor that should be taken into 
account. The main goal of treatment is to eliminate the 
inflammatory process by removing all the pathogens and 
the devitalised tissue, and if healing has not occurred, to 
promote healing by optimising the mechanical and bio-
logical environment. This can be achieved with a combina-
tion of treatment with antibiotic agents, surgical 
debridement and management of the dead space.
Great care should also be taken in diabetic patients. Symp-
toms may not be clear in these cases, whereas concomitant 
vascular compromise and peripheral neuropathy can compli-
cate the choice of treatment. A small but important percent-
age of these patients will require limb amputation.2
Antibiotic treatment
Initial empiric antibiotic treatment should be commenced 
as soon as the culture samples have been obtained. The 
antibiotic regimen should then be tailored to the results of 
the cultures and the sensitivities.6
Most authors recommend a four to six weeks’ duration 
of antibiotic therapy.3,5,23 This is based on the rationale that 
three to four weeks are required for the revascularisation of 
the bone, which gives a period of opportunity for the anti-
microbial agents to infiltrate the inflamed area and attack 
the pathogens which are at that point susceptible to 
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antibiotics.3,5 Nevertheless, no strong evidence supports 
this recommendation, or that prolonged antibiotic therapy 
reduces the rate of recurrence.5,23 In fact, prolonged antibi-
otic treatment is associated with increased risk of adverse 
events, costs and antibiotic resistance.23
The type of antibiotics and route of administration 
remain a matter of debate, with no clear evidence to guide 
practice. A recent Cochrane review by Conterno et al 
failed to show any difference between oral antibiotics 
compared with parenteral antibiotics in the rate of remis-
sion at the end of therapy and after 12 months or more of 
follow-up,3 a finding confirmed by other authors.5 The 
oral route of administration seems attractive, as if oral 
agents offer the same success with parenteral antibiotics, 
they have similar risks of adverse events but they are easier 
to administer and are associated with lower medical costs 
and reduced length of hospital stay.3,5
What is most important for the antibiotic agent used is 
the bone penetration it can achieve, as well as if it exceeds 
the minimum inhibitory concentrations for the isolated 
pathogen.5 The antibiotic regime used should also be 
based on the results of the cultures and sensitivities 
obtained by bone biopsies. In polymicrobial cases or in the 
presence of prosthetic infections, a combination of antibi-
otic agents is recommended as this has been reported to 
reduce the recurrence rate.5 Lastly, pathogens such as 
S.  aureus have been reported to acquire resistance to a 
number of antibiotics, a facet that makes treatment choice 
even more difficult.12
Additionally, local antibiotics in the form of polymeth-
ylmethacrylate (PMMA) beads can be used to deliver high 
doses of antibiotics to the surrounding tissues.20,24 Several 
studies have supported their effectiveness, with the addi-
tional advantage of managing the dead space resulting 
from the debridement.24,25 The antibiotic agent selected 
for the mixture should be active against the targeted bac-
terial pathogen. In contrast to the PMMA beads, calcium 
sulfate beads provide a more rapid release of high concen-
trations of antibiotics, having the advantage of being bio-
degradable and therefore precluding the need for 
removal.26 Similarly, hydroxyapatite-ceramic beads and 
polylactide-polyglycolide co-polymer implants are also 
biodegradable and have been successfully used in the 
treatment of chronic osteomyelitis.26
With regard to the choice of antibiotics, our recommen-
dation is to tailor treatment to each individual according to 
the type and extent of osteomyelitis, medical comorbidi-
ties, isolated organism(s) and whether this is the first pres-
entation or a recurrence. For common micro-organisms 
like S. aureus, we recommend treatment with IV Nafcillin 
or Cefazolin in case of methicillin-susceptible S. aureus 
(MSSA), and treatment with IV Vancomycin for MRSA. 
Most commonly, at least six weeks of antimicrobial ther-
apy is necessary, after which re-assessing the patient and 
further discussion with the microbiologists is advocated.
Surgical treatment
The cornerstone of the treatment of chronic osteomyelitis is 
surgical management (Table 2). This should include an ade-
quate surgical debridement to remove all pathogens along 
with their biofilms and sequestra (dead bone) that act as a 
foreign material, reaching down to healthy and viable tissue 
(Fig. 2a). The local soft tissue envelope should also be 
debrided and reconstructed if indicated. In cases of signifi-
cant extension of the osteomyelitis into the medullary canal, 
debridement with the reamer-irrigator-aspirator (RIA) tech-
nique and subsequent insertion of an antibiotic-impreg-
nated intramedullary cement rod has been suggested.20 
A more aggressive approach with reaming of the canal and, 
if involving a joint, the two adjacent canals, is advocated to 
decrease the risk of recurrence, as macroscopic determina-
tion of the extent of bone marrow infiltration is not reliable.
Adequate debridement should not be limited by any 
concerns of resulting osseous and/or soft-tissue defects,20 
as inadequate debridement has been associated with high 
incidence of recurrence.3 Following debridement, sam-
ples from the involved bone, sinus tract and surrounding 
tissues should be sent for pathological examination to 
ensure there are no malignant changes.20
Even though the need for surgical debridement in 
chronic osteomyelitis is unquestionable, many believe that 
it alone cannot sustain remission and that combination 
with antibiotics offers a better outcome.20 Though, one 
should bear in mind that not all cases of chronic osteomy-
elitis require surgical intervention, as the health state of the 
patient and the associated comorbidities that might be 
present could be a contraindication to operative interven-
tion, especially in the spine. In these cases suppressive 
treatment with appropriate antibiotics can be considered.
Management of dead space
Following an aggressive debridement that may be 
required to remove all devitalised tissue, a large bone 
defect (dead space) may be formed.3 This space needs 
appropriate management for the eradication of the infec-
tion and subsequent implantation of graft materials to 
allow bone regeneration.
In general terms, the choice of the reconstruction tech-
nique depends on the characteristics of the lesion follow-
ing the debridement and the physiological grading of the 
host. Primary bone grafting procedures are often not asso-
ciated with good success rates because of the resorption of 
the bone graft due to ongoing inflammation and/or 
 infection.2 Antibiotic-impregnated cement spacers and 
antibiotic beads can be used in cases of two-stage proce-
dures, temporarily filling the dead space until reconstruc-
tion is performed. The induced membrane (Masquelet) 
technique has also been used with encouraging results 
(Figs 2b, 2c and 3),27 and circular external fixation devices 
and bone transport is another option in managing critical 
size bone defects.27 Local flaps including muscle flaps, 
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Table 2. Different surgical techniques for treating chronic osteomyelitis
Surgical technique Advantages Disadvantages
Conventional reaming of the 
IM canal
- Clearance of intramedullary sepsis - Risk of fracture
- Risk of bleeding
-  Need for fenestration of the distal diaphysis to allow drainage of 
the irrigation fluids
RIA technique - Clearance of intramedullary sepsis
- Less traumatic than convectional reaming
- Risk of fracture
- Risk of bleeding
Primary bone grafting / bone 
graft substitutes
- Single-stage procedure
-  Superior osteoconductivity and osteoinductivity of 
the bone graft
- Confined to small defects / limited availability of bone graft
- Risk of early resorption / highly depends on the soft tissue bed
- Risk of relapse of infection
- Graft incorporation is slow and unreliable
- Donor site morbidity
Antibiotic-impregnated cement 
spacers / cement nails /
antibiotic beads
-  Slow release of high concentrations of antibiotics, 
avoiding their systemic effects
- Easy to mix - form into various shapes and sizes
-  Cement nails can provide some stability to 
associated fractures
-  Lack of biodegradability in some carriers / need for two-stage 
procedures
-  Concern that they can act as a foreign body, therefore harbouring 
infection
- Increased risk of antibiotic resistance
Bioactive glass -  Anti-microbial, osteoconductive and angiogenic 
properties
- Depends on good soft-tissue coverage
Induced membrane 
(Masquelet) technique
-  Combines the advantages of antibiotic-impregnated 
cement spacers with those of delayed bone grafting
-  The induced membrane is highly vascularised, rich in 
growth and osteoinductive factors
-  Offers a confined space for the application of the 
bone graft
- Two-stage procedure
- Increased risk of antibiotic resistance
- Limited availability of bone graft
- Can be associated with prolonged healing and recovery time
Circular external fixation 
devices and bone transport
- Increased blood flow in the area of corticotomy
- Minimally-invasive nature
-  Distraction is often limited because of the neurovascular bundle 
contracture
- Can be associated with pain for distraction > 2 cm
- Pin-site complications
- Need for specialised equipment
- Need for re-interventions
Local flaps -  Transfer of well-vascularised tissue that aids wound 
and bone healing
- Limited by pedicle length
- Donor-site morbidity
Vascularised free flaps -  Transfer of well-vascularised tissue that aids wound 
and bone healing
- Donor-site morbidity
- Need for microsurgical anastomoses
- Limited by peripheral artery disease
- Prolonged operating time
- High risk of early complications / risk of graft failure
Megaprosthesis - Restores limb function quickly
- No need for harvesting bone
- ‘One-shot’ surgery
- Risk of residual infection and early loosening
- Risk of dislocation
- Risk of revision surgery
Amputation - Early mobilisation
- One shot surgery
- Soft tissue reconstruction procedures
- Compromised function
- Regular revisions of the prosthetic limb
IM: intramedullary 
RIA: Reamer/Irrigator/Aspirator
  
 a) b) c)
Fig. 2 Following the excision of the sinus tract and radical surgical debridement of the impaired bone, a bone defect of 5 cm was 
formed. This was managed with a two-staged procedure (Masquelet technique). During the first stage, an antibiotic-loaded cement 
spacer was inserted, and the bone was stabilised with an external fixator. Two months later, the second stage involved incision of 
the induced membrane and removal of the cement spacer. The bone defect was subsequently filled with graft obtained from the 
ipsilateral femur using the RIA technique, mixed with BMP-7. Finally, the membrane was closed and the long bone was internally 
fixed. a) Radical debridement of the devitalised tissue and resulting bone defect; b) Induced membrane around the cement spacer, 
two months after the first stage procedure; c) Containment of the graft within the membrane.
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pedicled muscle flaps, myocutaneous flaps and osseous 
flaps have been used to optimise the impaired soft tissue 
envelope, with good results.6,19,20,28. Vascularised free flaps 
have also been used to cover large defects where the local 
tissues are impaired.6,19,20
Recently, the use of materials such as bioactive glass, in 
concurrence with antibiotic therapy, has been reported as 
safe and effective as a bone substitute in the presence of 
infection.29 Bioactive glass is a synthetic, biocompatible 
material that combines osteoconductive, angiogenic and 
antimicrobial properties, resulting in its integration into 
bone and soft tissues, thus becoming a potentially useful 
adjunct in the management of dead space.29
Complications
Numerous complications may arise due to the chronic 
inflammation and infective process. Abscess formation, 
sinus tracts and extension to adjacent structures are some 
of the most commonly encountered complications. None-
theless, the most important, easily missed complication is 
that of malignant transformation of chronic osteomyelitis, 
also referred to as Marjolin’s ulcer.19 The incidence of Mar-
jolin’s ulcer is higher in developing countries with limited 
medical resources, whereas it occurs in 1.6% to 23% of all 
patients with chronic osteomyelitis.30-32 Marjolin’s ulcers 
mainly involve aggressive squamous cell carcinomas 
(SCC), with a latent period of 27 to 30 years from onset of 
osteomyelitis to malignant transformation. The long dura-
tion of chronic osteomyelitis is the single most important 
predictive factor.30,31,33
Summary and conclusions
Chronic osteomyelitis continues to be a serious health 
problem worldwide, while representing an economic 
burden to any health system. Its occurrence, type, severity 
and prognosis depend on various factors, including the 
characteristics and virulence of the infecting pathogen, 
the physiological class of the host and the mechanism 
(source) of the infection. Before the initiation of treatment, 
it is very important that the causal host comorbidities, 
such as diabetes and peripheral vascular disease, are 
addressed. On the other hand, prevention of osteomyelitis 
in the form of focussed antibiotic prophylaxis in surgical 
and traumatic wounds, as well in prosthetic surgery, is of 
paramount importance.
The ‘gold standard’ for the diagnosis of chronic osteo-
myelitis is the presence of positive bone cultures and his-
topathological examination of the bone. Fluoro deoxy- 
glucose PET is the imaging technique with the highest 
diagnostic accuracy, but because of its limited availability, 
leucocyte scintigraphy can be used as an alternative in the 
peripheral skeleton.
The management of chronic osteomyelitis is challeng-
ing to the treating physician, complicated by the presence 
of infection, sequestra and impaired local vascularity with 
a compromised tissue envelope. A multidisciplinary 
approach involving radiologists, microbiologists with 
expertise in infectious diseases, orthopaedic surgeons and 
plastic-reconstructive surgeons is advocated. The treating 
physician should individualise treatment according to the 
patient’s severity and duration of symptoms, as well as 
the clinical and radiological response to treatment. A com-
bined antimicrobial and surgical treatment should be con-
sidered in all cases, as well as appropriate dead space 
management and later skeletal reconstruction. Even fol-
lowing long periods of antibiotic treatment and recurrent 
surgical debridement, exacerbations can occur for many 
years. The follow-up is still a matter of debate, but most 
experts agree that this should be as long as five years, as 
incidence of relapse remains high.
A sound understanding of the aetiology, mechanisms 
of infection and pathophysiology of the chronicity of 
chronic osteomyelitis can aid the treating physician in 
individualising treatment for each patient. Further research 
on the biokinetics of the different pathogens, including 
the biofilm properties, can help in the development of 
novel therapies for treating chronic osteomyelitis.
 
 a) b)
Fig. 3 Radiographs taken nine months post-revision surgery, 
showing good incorporation of the graft and continuity of 
the tibia. a) Anteroposterior (AP) radiograph; b) lateral (LAT) 
radiograph.
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